Phio Capital Expenditures vs Begin Period Cash Flow Analysis

PHIO Stock  USD 1.76  0.02  1.15%   
Phio Pharmaceuticals financial indicator trend analysis is much more than just breaking down Phio Pharmaceuticals Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Phio Pharmaceuticals Corp is a good investment. Please check the relationship between Phio Pharmaceuticals Capital Expenditures and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Phio Pharmaceuticals Corp Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Phio Pharmaceuticals' Capital Expenditures and Begin Period Cash Flow is 0.52. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Phio Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Phio Pharmaceuticals' Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Phio Pharmaceuticals Corp are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Phio Pharmaceuticals' Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.52
Relationship DirectionPositive 
Relationship StrengthWeak

Capital Expenditures

Capital Expenditures are funds used by Phio Pharmaceuticals Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Phio Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Phio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Phio Pharmaceuticals Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
At this time, Phio Pharmaceuticals' Issuance Of Capital Stock is very stable compared to the past year. As of the 22nd of December 2024, Sales General And Administrative To Revenue is likely to grow to 211.86, while Selling General Administrative is likely to drop about 4.2 M.
 2023 2024 (projected)
Reconciled Depreciation187K117.1K
Non Recurring4.2M3.8M

Phio Pharmaceuticals fundamental ratios Correlations

-0.050.650.620.90.010.25-0.97-0.580.030.970.071.0-0.04-0.590.3-0.10.480.64-0.020.021.00.27-0.59-0.040.33
-0.05-0.050.070.090.45-0.340.070.370.06-0.10.5-0.060.66-0.17-0.72-0.22-0.26-0.18-0.25-0.57-0.060.27-0.170.660.28
0.65-0.050.840.58-0.210.27-0.63-0.29-0.10.62-0.140.66-0.02-0.320.14-0.110.140.340.0-0.120.660.0-0.32-0.020.26
0.620.070.840.630.10.4-0.56-0.30.160.570.20.62-0.01-0.310.12-0.330.10.33-0.2-0.030.61-0.18-0.31-0.010.19
0.90.090.580.630.110.53-0.87-0.70.260.880.170.89-0.06-0.690.37-0.520.50.79-0.460.130.890.02-0.69-0.060.4
0.010.45-0.210.10.110.07-0.030.010.020.040.97-0.020.47-0.03-0.25-0.170.130.12-0.19-0.05-0.01-0.1-0.030.47-0.22
0.25-0.340.270.40.530.07-0.24-0.740.50.280.070.23-0.51-0.310.72-0.760.470.67-0.710.650.25-0.69-0.31-0.510.02
-0.970.07-0.63-0.56-0.87-0.03-0.240.580.06-1.0-0.1-0.97-0.010.6-0.290.09-0.47-0.670.020.0-0.97-0.240.6-0.01-0.41
-0.580.37-0.29-0.3-0.70.01-0.740.58-0.36-0.610.0-0.570.50.75-0.790.5-0.68-0.950.45-0.63-0.570.130.750.5-0.07
0.030.06-0.10.160.260.020.50.06-0.36-0.050.110.03-0.1-0.160.12-0.530.080.32-0.520.140.03-0.48-0.16-0.10.25
0.97-0.10.620.570.880.040.28-1.0-0.61-0.050.10.97-0.05-0.610.33-0.110.480.68-0.030.050.970.22-0.61-0.050.39
0.070.5-0.140.20.170.970.07-0.10.00.110.10.030.52-0.1-0.3-0.210.090.14-0.22-0.110.04-0.1-0.10.52-0.07
1.0-0.060.660.620.89-0.020.23-0.97-0.570.030.970.03-0.04-0.590.29-0.080.450.630.00.01.00.28-0.59-0.040.36
-0.040.66-0.02-0.01-0.060.47-0.51-0.010.5-0.1-0.050.52-0.040.24-0.830.2-0.28-0.250.14-0.85-0.050.20.241.00.21
-0.59-0.17-0.32-0.31-0.69-0.03-0.310.60.75-0.16-0.61-0.1-0.590.24-0.410.43-0.44-0.780.39-0.31-0.59-0.341.00.24-0.28
0.3-0.720.140.120.37-0.250.72-0.29-0.790.120.33-0.30.29-0.83-0.41-0.340.630.64-0.290.870.3-0.2-0.41-0.83-0.25
-0.1-0.22-0.11-0.33-0.52-0.17-0.760.090.5-0.53-0.11-0.21-0.080.20.43-0.34-0.18-0.520.99-0.34-0.10.520.430.2-0.23
0.48-0.260.140.10.50.130.47-0.47-0.680.080.480.090.45-0.28-0.440.63-0.180.69-0.170.510.480.13-0.44-0.28-0.34
0.64-0.180.340.330.790.120.67-0.67-0.950.320.680.140.63-0.25-0.780.64-0.520.69-0.50.450.64-0.07-0.78-0.250.17
-0.02-0.250.0-0.2-0.46-0.19-0.710.020.45-0.52-0.03-0.220.00.140.39-0.290.99-0.17-0.5-0.31-0.010.510.390.14-0.22
0.02-0.57-0.12-0.030.13-0.050.650.0-0.630.140.05-0.110.0-0.85-0.310.87-0.340.510.45-0.310.02-0.29-0.31-0.85-0.38
1.0-0.060.660.610.89-0.010.25-0.97-0.570.030.970.041.0-0.05-0.590.3-0.10.480.64-0.010.020.27-0.59-0.050.34
0.270.270.0-0.180.02-0.1-0.69-0.240.13-0.480.22-0.10.280.2-0.34-0.20.520.13-0.070.51-0.290.27-0.340.2-0.09
-0.59-0.17-0.32-0.31-0.69-0.03-0.310.60.75-0.16-0.61-0.1-0.590.241.0-0.410.43-0.44-0.780.39-0.31-0.59-0.340.24-0.28
-0.040.66-0.02-0.01-0.060.47-0.51-0.010.5-0.1-0.050.52-0.041.00.24-0.830.2-0.28-0.250.14-0.85-0.050.20.240.21
0.330.280.260.190.4-0.220.02-0.41-0.070.250.39-0.070.360.21-0.28-0.25-0.23-0.340.17-0.22-0.380.34-0.09-0.280.21
Click cells to compare fundamentals

Phio Pharmaceuticals Account Relationship Matchups

Phio Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets8.0M15.7M25.2M12.8M9.4M12.4M
Other Current Liab27K1.2M2.5M890K907K1.2M
Total Current Liabilities1.9M2.2M3.1M1.8M1.6M2.2M
Total Stockholder Equity5.7M13.0M21.9M10.8M7.7M8.1M
Property Plant And Equipment Net721K557K416K344K39K37.1K
Net Debt(6.4M)(13.6M)(23.8M)(11.5M)(8.5M)(8.9M)
Retained Earnings(94.8M)(103.6M)(116.9M)(128.4M)(139.2M)(132.2M)
Accounts Payable809K728K283K779K657K647.1K
Cash6.9M14.2M24.1M11.8M8.5M10.8M
Non Current Assets Total739K575K443K368K42K39.9K
Cash And Short Term Investments6.9M14.2M24.1M11.8M8.5M11.5M
Common Stock Shares Outstanding38.4K42.4K118.7K126.2K231.5K243.1K
Liabilities And Stockholders Equity8.0M15.7M25.2M12.8M9.4M12.4M
Other Current Assets316K920K670K665K832K489.5K
Other Stockholder Equity100.6M116.6M138.8M139.2M146.9M88.9M
Total Liab2.3M2.7M3.2M2.0M1.6M3.1M
Property Plant And Equipment Gross721K557K416K344K1.2M1.2M
Total Current Assets7.3M15.2M24.7M12.4M9.3M12.1M
Property Plant Equipment172K210K557K416K478.4K268.2K
Net Tangible Assets13.6M5.7M13.0M21.9M25.2M26.5M
Retained Earnings Total Equity(78.6M)(85.9M)(94.8M)(103.6M)(93.3M)(97.9M)
Capital Surpluse80.4M99.5M100.6M116.6M134.1M86.0M
Net Invested Capital5.7M13.2M21.9M10.8M7.7M11.8M
Net Working Capital5.4M13.0M21.7M10.5M7.7M11.5M

Pair Trading with Phio Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Phio Stock

  0.69ME 23Andme HoldingPairCorr
  0.63VALN Valneva SE ADRPairCorr

Moving against Phio Stock

  0.58SABSW SAB BiotherapeuticsPairCorr
  0.55VCEL Vericel Corp OrdPairCorr
  0.44VCYT VeracytePairCorr
  0.37CDIOW Cardio DiagnosticsPairCorr
  0.36DMAC DiaMedica Therapeutics Upward RallyPairCorr
The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(14.81)
Return On Assets
(0.61)
Return On Equity
(1.27)
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.